What is Parkinson Study Group?
As the largest non-profit clinical trial site network dedicated to Parkinson's disease, the Parkinson Study Group serves as a vital bridge between academic research and patient-centric clinical outcomes. The organization operates as a collaborative ecosystem, uniting more than 375 credentialed investigators to streamline the complexities of drug development and therapeutic validation. By maintaining a high standard of research integrity and providing mentorship to emerging investigators, the PSG effectively mitigates the operational risks typically associated with multi-site neurological studies. Its market position is defined by its unique ability to mobilize a vast, specialized workforce to accelerate the pace of medical discovery in a highly competitive and demanding therapeutic landscape.
How much funding has Parkinson Study Group raised?
Parkinson Study Group has raised a total of $115M across 1 funding round:
Other Financing Round
$115M
Other Financing Round (2016): $115M with participation from PDF
Key Investors in Parkinson Study Group
A specialized entity operating within the consumer services sector, providing strategic support to research-focused organizations.
What's next for Parkinson Study Group?
With the recent influx of capital, the Parkinson Study Group is poised to enter a new phase of operational scaling and infrastructure enhancement. The strategic roadmap focuses on the expansion of its clinical trial footprint, aiming to integrate additional high-caliber research sites to increase patient access and data diversity. Furthermore, the organization is expected to deepen its investment in mentorship initiatives, ensuring that the next generation of neurological researchers is equipped with the necessary resources to navigate the evolving regulatory and scientific environment. By prioritizing collaborative innovation and site-level efficiency, the PSG is well-positioned to maintain its leadership in the fight against Parkinson's disease, ultimately driving the development of next-generation treatments that address the unmet needs of the global patient population.
See full Parkinson Study Group company page
